-REX-7117 is an oral, potent and selective STAT3 SH2 domain inhibitor, which demonstrated strong efficacy in an in vivo model of inflammatory arthritis -STAT3 inhibition does not impair the interferon ...
--In a preclinical model of psoriasis, the efficacy of oral small molecule REX-7117 was comparable to an anti-IL-17A biologic SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in ...
VVD-130850 is an investigational oral small molecule inhibitor of STAT3 transcription factor developed for treatment of advanced solid and hematologic tumors as a single agent and in combination with ...
Altay Therapeutics Inc. has divulged signal transducer and activator of transcription 3 (STAT3) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, diabetes, inflammatory ...
HOUSTON, Sept. 9, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio of drug candidates ...
Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, ...
Vividion Therapeutics Inc. has patented 2-azaspiro [3.3]heptane derivatives acting as signal transducer and activator of transcription 3 (STAT3) inhibitors potentially useful for the treatment of ...
Head and neck squamous cell carcinoma (HNSCC) is approximately the seventh most common cancer in humans with an estimated 900,000 new cases globally. As a surgeon, Jennifer Grandis, MD, a physician ...
Schematic diagram of the IL-6/JAK/STAT3 signaling pathway activation in mouse liver macrophages. IRs, inhibitory receptors (IRs); ICIs, immune checkpoint inhibitors; IL-6, interleukin-6; ALT, alanine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results